HL237
/ Hanlim Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 18, 2020
The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus
(clinicaltrials.gov)
- P1; N=24; Active, not recruiting; Sponsor: Hanlim Pharm. Co., Ltd.
Clinical • New P1 trial
November 20, 2020
Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis
(clinicaltrials.gov)
- P2a; N=196; Enrolling by invitation; Sponsor: Hanlim Pharm. Co., Ltd.
Clinical • New P2a trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
1 to 2
Of
2
Go to page
1